References
- Cheng C, Byon W, Lu Y, et al. (2012). Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS 13:565–75
- Dalvie DK, Obach RS, Kang P, et al. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–68
- Gibbs JP, Hyland R, Youdim K. (2006). Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab Dispos 34:1516–22
- Grimwood S, Lu Y, Schmidt AW, et al. (2011). Pharmacological characterization of 2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa-opioid receptors. J Pharmacol Exp Ther 339:555–66
- Inoue H, Castagnoli K, Van Der Schyf C, et al. (1999). Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 291:856–64
- Kalgutkar AS, Dalvie DK, Castagnoli N, et al. (2001). Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 14:1139–62
- Kamel A, Obach RS, Tseng E, et al. (2010). Metabolism, pharmacokinetics and excretion of the GABA(A) receptor partial agonist [(14)C]CP-409,092 in rats. Xenobiotica 40:400–14
- Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359–69
- Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
- Obach RS. (2001). The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Develop 4:36–44
- Obach RS. (2010). Predicting clearance in humans from in vitro data. Curr Top Med Chem 11:334–9
- Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
- Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–53
- Prentis RA, Lis Y, Walker RS. (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964--1985). Br J Clin Pharmacol 25:387–96
- Sawant AD, Miller EL, Duignan DB, et al. (2010). Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica 40:476–84
- Steijns LS, Van der Weide J. (1998). Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44:914–17
- Verhoest PR, Basak AS, Parikh V, et al. (2011). Design and discovery of a selective small molecule kappa opioid antagonist (2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem 54:5868–77
- Walsky RL, Obach RS, Hyland R, et al. (2012). Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686–97